Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy (EXCALIBUR)

NCT04915508 PHASE2 RECRUITING

This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Details

Lead sponsor	Jonsson Comprehensive Cancer Center
Phase	PHASE2
Status	RECRUITING
Enrolment	102
Start date	Wed Jun 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Aug 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Prostate Adenocarcinoma
• Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
• Stage IIIC Prostate Cancer AJCC v8
• Stage IV Prostate Cancer AJCC v8
• Stage IVA Prostate Cancer AJCC v8
• Stage IVB Prostate Cancer AJCC v8

Interventions

• Hormone Therapy
• Stereotactic Body Radiation Therapy

Countries

United States